Search results
Showing 2801 to 2850 of 4091 results for patient
Check to see if you're entitled to access a range of content purchased by the NHS. If you are eligible, you can register for an OpenAthens account using our online form.
Evidence-based recommendations on loncastuximab tesirine (Zynlonta) for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments.
This indicator covers the percentage of patients with very severe chronic obstructive pulmonary disease (COPD) with a record of oxygen saturation value within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM194
Evidence-based recommendations on scleral expansion surgery for presbyopia. This involves making small incisions in the eye and inserting bands to stretch part of the sclera.
View recommendations for HTG43Show all sections
Sections for HTG43
sodium zirconium cyclosilicate improved length or quality of life or allowed patients to stay on optimal doses of...
Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (HTG735)
Evidence-based recommendations on home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome.
Optical coherence tomography to guide percutaneous coronary intervention (HTG332)
Evidence-based recommendations on optical coherence tomography to guide percutaneous coronary intervention. This involves using near-infrared light to produce high-resolution images of blood vessel walls.
Evidence-based recommendations on stimulated graciloplasty for faecal incontinence. This involves making a new anal sphincter from muscle taken from the thigh and using electrical currents to gradually make it behave like a natural sphincter muscle.
View recommendations for HTG103Show all sections
Sections for HTG103
reactions to non-selective non-steroidal anti-inflammatory drugs:- Should all patients who have experienced a severe allergic reaction...
This guideline sets out an antimicrobial prescribing strategy for insect and spider bites and stings in adults, young people and children aged 72 hours and over, including those that occurred while travelling outside the UK. It aims to limit antibiotic use and reduce antibiotic resistance.
View recommendations for NG182Show all sections
NICE has developed a medtech innovation briefing (MIB) on Colli-Pee for first void urine collection .
This guideline covers oral health, including dental health and daily mouth care, for adults in care homes. The aim is to maintain and improve their oral health and ensure timely access to dental treatment.
Evidence-based recommendations on low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing in adults. This involves using an ultrasound probe on the skin at the site of the fracture.
View recommendations for HTG479Show all sections
Digital tools and platforms to support the early detection and initial diagnosis of hearing loss
Awaiting development Reference number: GID-HTE10088 Expected publication date: TBC
Awaiting development Reference number: GID-HTE10083 Expected publication date: TBC
Digital AI tools in histopathology (breast and prostate cancer)
Awaiting development Reference number: GID-HTE10087 Expected publication date: TBC
people with multiple sclerosis. There were reductions in some measures of patient-reported spasticity and no difference in adverse...
This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.
This indicator covers the percentage of patients with cancer, diagnosed within the preceding 12 months, who have had a discussion within 3 months of diagnosis about the support available from primary care. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM204
This indicator covers the percentage of patients with COPD and Medical Research Council (MRC) Dyspnoea Scale of 3 or more at any time in the preceding 15 months, with a subsequent record of an offer of referral to a pulmonary rehabilitation programme. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM47
CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)
NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .
This indicator covers the proportion of people with chronic obstructive pulmonary disease (COPD) and Medical Research Council (MRC) dyspnoea scale 3 and above who are referred to a pulmonary rehabilitation programme. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG08.
Developmental follow-up of children and young people born preterm (NG72)
This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.
The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound
Awaiting development Reference number: GID-MT603 Expected publication date: TBC
Evidence-based recommendations on anhydrous sodium thiosulfate (Pedmarqsi) for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours.
This quality standard covers road-traffic-related air pollution and its impact on health. It describes high-quality actions in priority areas for improvement.
View quality statements for QS181Show all sections
Sections for QS181
- Quality statements
- Quality statement 1: Strategic plans
- Quality statement 2: Planning applications
- Quality statement 3: Reducing emissions from public sector vehicle fleets
- Quality statement 4: Advice for people with chronic respiratory or cardiovascular conditions
- Update information
- About this quality standard
This indicator covers the percentage of patients on the learning disability register with Down's Syndrome aged 18 and over who have a record of blood TSH in the previous 15 months (excluding those who are on the thyroid disease register). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM04
Evidence-based recommendations on laparoscopic distal pancreatectomy. This involves removing the left part of the pancreas through small cuts (keyhole surgery) in the upper abdomen.
View recommendations for HTG130Show all sections
Sections for HTG130
Evidence-based recommendations on therapeutic hypothermia for acute ischaemic stroke in adults. This involves using a cooling device to reduce the body’s temperature after a stroke.
View recommendations for HTG511Show all sections
Ultrasound-guided catheterisation of the epidural space (HTG160)
Evidence-based recommendations on ultrasound-guided catheterisation of the epidural space. This involves using ultrasound scanning to guide a catheter into the space inside the spine to give pain relief or an anaesthetic.
View recommendations for HTG160Show all sections
Sections for HTG160
Evidence-based recommendations on endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for gastro-oesophageal reflux. This involves inserting hydrogel implants into the wall of the oesophagus to narrow the entrance to the stomach and help prevent reflux.
View recommendations for HTG142Show all sections
Sections for HTG142
Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome (HTG235)
Evidence-based recommendations on percutaneous posterior tibial nerve stimulation for overactive bladder syndrome. This involves inserting a fine needle into a nerve just above the ankle and passing a mild electric current to the nerves that control bladder function.
View recommendations for HTG235Show all sections
Sections for HTG235
BRAHMS copeptin assay to rule out myocardial infarction in patients with acute chest pain (MTG4)
In November 2016, NICE reviewed this guidance and recommended that it should be withdrawn. The guidance was published in June 2011 and recommended that further research was carried out on the technology. There was insufficient evidence on its use in clinical practice to recommend adoption. On reviewing the guidance in 2016, NICE determined that: The comparator in the original guidance, standard serial troponin testing, was changed in 2014 to high sensitivity troponin testing which expert advice indicated is now widespread in the NHS The clinical pathway in the original evaluation has significantly changed and the original scope is no longer valid. These changes mean that the current guidance is no longer valid and NICE would not be able to update it. The guidance has therefore been withdrawn. For a copy of the review decision please contact nice@nice.org.uk.
This guidance has been updated and replaced by NICE guideline NG107
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing and managing COPD in over 16s and for people with COVID-19 see our guideline on managing COVID-19.
This indicator covers the percentage of patients with non-diabetic hyperglycaemia who have had an HbA1c test or FPG test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM150
This indicator covers the establishing and maintaining of a register of all patients with a diagnosis of non-diabetic hyperglycaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM148
This indicator covers the percentage of patients with diabetes with a record of testing of foot sensation using a 10 g monofilament within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM131
What is the optimal antibiotic prophylaxis regimen for women who are having a surgical abortion?
doxycycline in the rates of pelvic inflammatory disease after abortion, patient adherence, vomiting, or diarrhoea. The committee...
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]
Awaiting development Reference number: GID-TA11088 Expected publication date: TBC
Myocardial infarction: measurement of ejection fraction (IND75)
This indicator covers the proportion of patients with acute myocardial infarction with measurement of left ventricular ejection fraction before discharge. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG94
This indicator covers registering patients with a clinical diagnosis of COPD before (start date), and patients with a clinical diagnosis of COPD on or after (start date) whose diagnosis has been confirmed by a quality assured post bronchodilator spirometry FEV1/FVC ratio below 0.7 between 3 months before or 3 months after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM169
Awaiting development Reference number: GID-IPG10419 Expected publication date: TBC
controlled trials comparing the procedure with placebo. It should report patient selection and treatment protocols, including the number...
Consultation on changes to technology appraisals and highly specialised technologies
arrangements for funding others more clear. The proposed changes will benefit patients by providing access to the most effective and...
NICE announces Professor Jonathan Benger as new Chief Executive
NICE Chairman, Sharmila Nebhrajani, today announced Professor Jonathan Benger CBE as incoming chief executive, with effect from Friday 19 December 2025 taking over from Dr Samantha Roberts.
Urinary tract infection (recurrent): antimicrobial prescribing (NG112)
This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
Bipolar, schizophrenia and other psychoses: cervical screening (50 to 64 years) (IND214)
This indicator covers the percentage of women aged 50 or over and who have not attained the age of 65 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 5 years and 6 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM196
Bipolar, schizophrenia and other psychoses: cervical screening (25 to 49 years) (IND213)
This indicator covers the percentage of women aged 25 or over and who have not attained the age of 50 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 3 years and 6 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM195